Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials

Abstract

The objective of this study was to identify reliable and valid instruments to measure cognitive impairment in systemic lupus erythematosus (SLE), and to define minimally important change of cognitive impairment in SLE for clinical trials. Neurocognitive measures used in randomized clinical trials in SLE were reviewed, and response criteria were developed using consensus expert opinion. The definition of cognitive impairment in the ACR nomenclature for neuropsychiatric lupus syndrome was adopted. Cognitive impairment is a deficit of 2.0 or more standard deviations (SD) below the mean, compared to normative data, in the key domains of attention, memory and psychomotor speed. Cognitive decline is defined as a deficit of 1.5—1.9 SD below the mean. Focal decline is defined if impairment exists in one or more measures within one domain, and multifocal decline if impairment exists on measures spanning two or more domains. The combination of ACR neuropsychological battery and the Cognitive Symptoms Inventory (CSI) is recommended to quantitate cognitive function. A clinically important response is defined as an improvement of ≥ 1.0 SD with an effect size of 1.0 in the key domains of the ACR neuropsychological testing, and an improvement of ≥ 1.0 SD with an effect size of 1.0 in functional performance of the CSI. Lupus (2007) 16, 418—425

Keywords

clinical trials cognitive function cognitive impairment neuropsychological testing response criteria

Get full access to this article

View all access options for this article.

References

American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity. Arthritis & Rheumatism 2004; 50: 3418—3426.

Liang M. , Schur P. , Fortin P. et al. The American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials . Arthritis & Rheumatism 2006; 54: 421—432.

Kremer JN , Rynes RI , Bartholomew LE et al. Non-organic non-psychotic psychopathology (NONPP) in patients with systemic lupus erythematosus. Seminars Arthritis Rheum 1981; 11: 182—189.

Alarcón GS , Cianfrini L. , Bradley LA et al. Systemic lupus erythematosus in three ethnic groups: Measuring cognitive impairment with the cognitive symptoms inventory. Arthritis Rheum 2002; 47: 310—319.

Hanly JG , Fisk JD , Sherwood G. , Eastwood B. Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1994; 10: 1825—1831.

Hanly JG , Cassell K. , Fisk JD Cognitive function in systemic lupus erythematosus: result of 5-year prospective study. Arthritis Rheum 1997; 40: 1542—1543.

Denburg SD , Carbotte RM , Denburg JA Cognition and mood in systemic lupus erythematosus. Evaluation and pathogenesis . Ann N Y Acad Sci 1997; 823: 44—59.

Brey RL , Holliday SL , Saklad AR et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214—1220.

Ad hoc Committee. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599—608.

10.

Kaplan H. , Sadock B. Comprehensive textbook of psychiatry, 7th edition. Williams & Wilkins, 2000.

11.

Lezak MD , Howieson DB , Loring DW Neuropsychological assessment, 4th edition. Oxford University Press, 2004.

12.

Pincus T. , Swearingen C. , Callahan LF A self-report cognitive symptoms inventory to assess patients with rheumatic diseases: Results in eosinophilia-myalgia syndrome (EMS), fibromyalgia, rheumatoid arthritis (RA), and other rheumatic diseases. Arthritis Rheum 1996; 39: S261.

13.

Jadad AR , Cook DJ , Jones A. et al. Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals . JAMA 1998; 280: 278—280.

14.

Takada K. , Jacobs G. , Lapteva L. et al. Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus . Arthritis & Rheum 2006; 55: 434—441.

15.

Glanz BI , Schur P. , Lew R. , Khoshbin S. Lateralized cognitive dysfunction in patients with systemic lupus erythematosus . Lupus 2005; 14: 896—902.

16.

Doninger NA , Fink JW , Utset TO

Neuropsychologic functioning and health status in systemic lupus erythematosus: does ethnicity matter?

J Clin Rheumatol 2005; 11: 250—256.

17.

Emori A. , Matsushima E. , Aihara O. et al. Cognitive dysfunction in systemic lupus erythematosus. Psychiatry Clin Neurosci 2005; 59: 584—589.

18.

Shucard JL , Parrish J. , Shucard DW , McCabe DC , Benedict RH , Ambrus J Jr. Working memory and processing speed deficits in systemic lupus erythematosus as measured by the paced auditory serial addition test. J Int Neuropsychol Soc 2004; 10: 35—45.

19.

Kozora E. , Ellison MC , West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004; 51: 810—818.

20.

Loukkola J. , Laine M. , Ainiala H. et al. Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. J Clin Exp Neuropsychol 2003; 25: 145—151.

21.

Leritz E. , Brandt J. , Minor M. , Reis-Jensen F. , Petri M. Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. J Clin Exp Neuropsychol 2002; 24: 527—533.

22.

Kozora E. , Laudenslager M. , Lemieux A. , West SG Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. J Int Neuropsychol Soc 2001; 7: 745—754.

23.

Monastero R. , Bettini P. , Del Zotto E et al. Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J Neurol Sci 2001; 184: 33—39.

24.

Ainiala H. , Loukkola J. , Peltola J. , Korpela M. , Heitaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus . Neurology 2001; 57: 276—283.

25.

Gladman DD , Urowitz MB , Slonim D. et al. Evaluation of predictive factors for neurocognitive dysfunction in patients with inactive systemic lupus erythematosus. J Rheumatol 2000; 27: 2367—2371.

26.

Skeel Rl, Johnstone B, Yangco DT, Walker SE, Komatireddy GR. Neuropsychological deficit profiles in systemic lupus erythematosus. Appl Neuropsychol 2000; 7: 96—101.

27.

Carlomagno S. , Migliaresi S. , Ambrosone L. , Sannino M. , Sangnes G. , Di Lorio G. Cognitive impairment in systemic lupus erythematosus: a follow up study. J Neurol 2000; 247: 273—279.

28.

Sabbadini MG , Manfredi AA , Bozzolo E. et al. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations . Lupus 1999; 8: 11—19.

29.

Breitbach S. , Alexander R. , Daltry L. et al. Determinants of cognitive performance in systemic lupus erythematosus. J Clin Exp Neuropsychol 1998; 20: 157—166.

30.

Glanz BI , Slonim D. , Urowitz MB , Gladman DD , Gough J. , MacKinnon A. Pattern of neuropsychologic dysfunction in inactive systemic lupus erythematosus . Neuropsychiatry Neuropsychol Behav Neurol 1997; 10: 232—238.

31.

Kozora E. , Thompson LL , West SG , Kotzin BL Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1996; 39: 2035—2045.

32.

Carbotte RM , Denburg SD , Denburg JA Cognitive dysfunction in systemic lupus erythematosus is independent of active disease. J Rheumatol 1995; 22: 863—867.

33.

Hanly J. , Fisk J. , Sherwood G. , Jones E. , Jones J. , Eastwood B. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 1992; 19: 562—567.

34.

Hay EM , Black D. , Huddy A. et al. Psychiatric disorder and cognitive impairment in SLE. Arthritis Rheum 1992; 35: 411—416.

35.

Ferstl R. , Niemann T. , Biehl G. , Hinrichsen H. , Kirch W. Neuropsychological impairment in auto-immune disease. Eur J Clin Invest 1992; 22(Suppl 1): 16—20.

36.

Ginsburg KS , Wright EA , Larson MG et al. A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. Arthritis Rheum 1992; 35: 776—782.

37.

Wekking E. , Nossent J. , van Dam A. , Swaak A. Cognitive and emotional disturbances in systemic lupus erythematosus. Psychother Psychosom 1991; 55: 126—131.

38.

Denburg SD , Carbotte RM , Denburg JA Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. J Clin Exp Neuropsychol 1987; 9: 323—339.

39.

Carbotte RM , Denburg SD , Denburg JA Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986; 174: 357—364.

40.

Folstein MF , Folstein SE , McHugh PR Mini-mental state. J Psychiatr Res 1975; 12: 189—198.

41.

Nelson A. , Fogel BS , Faust D. Bedside cognitive screening instruments: a critical assessment. J Nerv Ment Dis 1986; 174: 73—83.

42.

Keirnan RJ , Mueller J. , Langstone JW , van Dyke C. The neurobehavioral cognitive status examination. Ann Intern Med 1987; 107: 481—485.

43.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. TR Plus, 4th edition. American Psychiatric Association , 2000.

44.

Smith RC , Infante M. , Singh A. , Khandat A. The effects of olanzapine on neurocognitive functioning in medication refractory schizophrenia. Int J Neuropsychpharmacol 2001 ; 4: 239—250.

45.

Cohen RA , Boland R. , Paul R. et al. Neurocognitive performance enhanced by highly active retroviral therapy in HIV infected women. AIDS 2001; 15: 341—345.

46.

Grigore AM , Grott HP , Mathew JP et al. The rewarming rate and increased peak temperature alter neurocognitive outcome after cardiac surgery. Anesth Analg 2002; 94: 4—10.

47.

Barak Y. , Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis . Eur Neurology 2002; 47: 11—14.

48.

Winblad B. , Engedal K. , Soininen H. et al. A one- year randomized placebo controlled study of donepezil in patients with mild to moderate AD. J Neurology 2001; 57: 489—495.

49.

Sweet JJ , Doninger NA , Zee PC , Wagner LI Factors influencing cognitive function, sleep, and quality of life in individuals with systemic lupus erythematosus: a review of the literature. Clin Neuropsychol 2004; 18: 132—147.

50.

Holliday SL , Navarrete MG , Hermosillo-Romo D. et al. Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus 2003; 12: 697—703.

51.

Sibbitt WL Jr , Sibbitt RR , Brooks WM Neuroimaging in neuropsychiatric lupus. Arthritis Rheum 1999, 42: 2026—2038.

52.

Kozora E. , Arciniegas D. , Filley C. et al. Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol 2005; 18: 159—162.

53.

Sailer M. , Burchert W. , Ehrenheim C. et al. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 1997; 244: 186—193.

54.

Komatsu N. , Kodama K. , Yamanouchi N. et al. Decreased regional cerebral metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms. Eur Neurol 1999; 42: 41—48.

55.

Kozora E. , West SG , Kotzin BL , Julian L. , Porter S. , Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease . Arthritis Rheum 1998; 41: 41—47.

56.

Waterloo K. , Omdal R. , Jacobsen EA et al. Cerebral computed tomography and electroencephalography compared with neuropsychological findings in systemic lupus erythematosus. J Neurology 1999; 246: 706—711.

57.

Waterloo K. , Omdal R. , Sjoholm H. et al. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow . J Neurol 2001; 248: 595—602.

58.

Bosma GP , Rood MJ , Huizinga TW et al. Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging. Arthritis Rheum 2000; 43: 2428—2436.

59.

Govoni M. , Castellino G. , Padovan M. , Borrelli M. , Trotta F. Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus. Lupus 2004; 13: 149—158.

60.

Steens SC , Admiraal-Behloul F. , Bosma GP et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum 2004; 50: 2877—2881.

61.

Hanly JG , Hong C. , Smith S. , Fisk JD A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 728—734.

62.

Denburg SD , Carbotte RM , Ginsberg JS , Denburg JA The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc 1997; 3: 377—386.

63.

64.

Afeltra A. , Garzia P. , Mitterhofer AP et al. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 2003; 61: 108—110.

65.

Menon S. , Jameson-Shortall E. , Newman SP , Hall-Craggs MR , Chinn R. , Isenberg DA A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 735—741.

66.

Kowal C. , DeGiorgio LA , Nakaoka T. et al. Cognition and immunity; antibody impairs memory. Immunity 2004; 21: 179—188.

67.

Long AA , Denburg SD , Carbotte RM , Singal DP , Denburg JA Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 249—253.

68.

Brooks WM , Jung RE , Ford CC , Grienel EJ , Sibbitt WL Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1999; 26: 81—85.

69.

Trysberg E. , Nylen K. , Rosengren LE , Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48: 2881—2887.

70.

Trysberg E. , Blennow K. , Zachrisson O. , Tarkowski A. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther 2004; 6: 551—556.

71.

Ainiala H. , Hietaharju A. , Dastidar P. et al. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum 2004; 50: 858—865.

72.

Sibbitt W. , Brandt J. , Johnson C. , Maldonado M. et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29: 1536—1542.

73.

Steinlin M. , Blaser S. , Gilday D. , Eddy A. et al. Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatric Neurology 1995; 13: 191—197.

74.

Klein-Gitelman MS , Zelko F. , Kress A. et al. Comparison of neurocognitive function in children with pediatric systemic lupus erythematosus (pSLE) and their peers — second year follow up. Arthritis Rheum 2002 ; 46: S216.

75.

Sattler JM Issues related to the measurement and change of intelligence. Assessment of children: cognitive applications, 4th edition. Sattler J.M., 2001: 160—182.

76.

Glutting JJ , Oakland T. , McDermott PA Observing child behavior during testing: Constructs, validity, and situational generality. Journal of School Psychology 1989 ; 27: 155—164.

77.

Ruth N. , German A. , Graham TB , Passo M. , Ris D. , Brunner HI Diagnosis of childhood-onset lupus neurocognitive impairment in a clinical setting: usefulness of computer based testing and self-report. Arthritis Rheum 2006; 54: S688.

78.

Denburg SD , Stewart KE , Hart LE , Denburg JA How “soft” are soft neurological signs? The relationship of subjective neuropsychiatric complaints to cognitive function in systemic lupus erythematosus . J Rheumatol 2003; 30: 1006—1010.

79.

Butcher JN , Perry J. , Hahn J. Computers in clinical assessment: historical developments, present status, and future challenges. J Clin Psychol 2004 ; 60: 331—345.

80.

Ojemann G. , Ojemann J. , Lettich E. Cortical language localizations in left, dominant hemisphere: an electrical stimulation mapping experiment in 117 patients. J Neurosurg 1989; 71: 316—326.

81.

Marshall JC The description and interpretation of aphasic language disorder. Neuropsychologia 1986; 24: 5—23.

82.

Hanly J. , Fisk J. , McCurdy G. , Fougere L. , Douglas J. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2005; 32: 1459—1464.